Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24145828 | 1.00 | ADCY1 (0.61) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL29032402 | 0.91 | ADCY1 (0.63) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL30343003 | 0.90 | KDM4E (0.72) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL24145812 | 0.90 | KDM4E (0.72) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL24145709 | 0.89 | ADCY1 (0.59) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL24145665 | 0.89 | ADCY1 (0.61) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL29032383 | 0.88 | ADCY1 (0.60) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL24154946 | 0.88 | ADCY1 (0.60) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL29032464 | 0.88 | ADCY1 (0.64) | ADCY1KDM4ELMNANPC1RAB9A | |
| SCHEMBL24145654 | 0.87 | ADCY1 (0.58) | ADCY1KDM4ELMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438174-A | Compounds and their use as MIF inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4168399-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | claimed |
| US-20240083912-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2024-03-14 | — | — | US | disclosed |
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-01-30 | — | — | US | disclosed |
| CN-116438174-A | Compounds and their use as MIF inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4168399-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | MIF, CCL11, CCL2 | ADCY1 2594/4885KDM4E 2841/4885LMNA 3977/4885 |
| US-20240083912-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | MIF, CCL11, CCL2 | ADCY1 2594/4885KDM4E 2841/4885LMNA 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.